Abivax SA (FR:ABVX)
:ABVX
Want to see FR:ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
€104.70
-€0.19(-2.81%)
At close: 4:00 PM EST
€104.70
-€0.19(-2.81%)
Day’s Range― - ―
52-Week Range€5.12 - €132.00
Previous CloseN/A
Volume4.35K
Average Volume (3M)99.97K
Market Cap
€6.79B
Enterprise Value€8.55B
Total Cash (Recent Filing)€530.38M
Total Debt (Recent Filing)€32.09M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Sep 21, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.83
Shares Outstanding79,770,190
10 Day Avg. Volume99,142
30 Day Avg. Volume99,970
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€125.00Price Target Upside19.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.55
Revenue Forecast (FY)€70.21M
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet / Low LeverageThe meaningful 2025 balance sheet improvement and debt at ~7% of equity materially reduces near-term refinancing pressure. This stronger capitalization provides financial flexibility to fund clinical programs and operations over the next 2-6 months without immediate forced restructuring.
High Historical Gross MarginsWhen revenue existed the company achieved near-100% gross margins, indicating attractive unit economics for its therapeutic candidate. If commercialized or partnered, these margin characteristics support sustainable profitability and high incremental margins once fixed R&D costs are covered.
Focused Clinical-stage Lead AssetA clear, focused pipeline centered on obefazimod provides strategic clarity and concentrated R&D effort. The oral small-molecule approach for chronic inflammatory diseases aligns with large addressable markets and durable clinical development pathways that can unlock value with successful trial/regulatory milestones.
Bears Say
Persistent Negative Free Cash FlowSustained negative free cash flow (≈-162M in 2025) shows the company cannot self-fund operations or pivotal studies. This ongoing burn necessitates external financing, raising dilution and execution risk, and constrains long-term strategic optionality absent a visible path to cash generation.
Revenue Volatility; 2025 Revenue Fell To ZeroA drop to zero reported revenue in 2025 highlights an absence of commercial traction and unpredictable top-line dynamics. Without recurring sales, the business depends on clinical success, partnerships, or financings to achieve sustainable revenue, increasing long-term commercialization risk.
Large, Widening Net Losses And Financing RelianceConsistent, widening net losses (2020–2025) and prior swings in leverage reflect a pattern of financing-driven survival rather than operational profitability. Recurrent capital raises and balance sheet actions increase dilution risk and may limit ability to invest countercyclically or pursue opportunistic partnerships.
Abivax SA News
ABVX FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €5.12 and its highest was €132.00 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €6.79B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Sep 21, 2026 which is in 101 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on May 22, 2026. The company reported -€0.61 earnings per share for the quarter, beating the consensus estimate of -€0.803 by €0.193.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.76.
How many shares outstanding does Abivax SA have?
Abivax SA has 79,770,190 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€0.61 in its last earnings report, beating expectations of -€0.803. Following the earnings report the stock price went up 8.687%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in FR:ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
ABVX Stock 12 Month Forecast
Average Price Target
€125.00
▲(19.39% Upside)
Technical Analysis
Options Prices
Currently, No data available
---